bluebird bio Inc at Credit Suisse Healthcare Conference Transcript
(technical difficulty) we're really excited to be here after a pretty transformative year for bluebird. We now have -- 2 of the 4 gene therapies approved in the U.S. just in a year ago, we were still a clinical development company and now we are fully a commercial company. We were really excited to launch both SKYSONA for cerebral adrenoleukodystrophy this year and ZYNTEGLO for beta thalassemia and that was following 2 unanimous AdComs in June. So those are both FDA-approved right now. We're going to be launching lovo-cel for sickle cell disease -- or sorry, excuse me, filing with the FDA (technical difficulty) the infrastructure that we're building right now for ZYNTEGLO in the U.S. will support that launch. So really a completely new chapter in bluebird's history, we're now a commercial company.
Questions & Answers
Fantastic. So what's the most frequent (inaudible) and bear argument (technical difficulty) no it's been a very exciting time for you guys. Can you talk
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
